Kao to Take Spain’s Chimigraf

Japanese chemical and cosmetics company Kao Corporation has concluded a deal to acquire Spanish inks company Chimigraf Holding for an undisclosed sum. Located in Barcelona with around 180 employees, Chimigraf develops, manufactures and sells flexographic and rotogravure inks for package printing.

Kao said Chimigraf has a wide range of products and versatile ink designing technologies. Having developed a business centered in Europe, the company was now looking to expand its sales worldwide. In particular, it is currently focused on developing inkjet ink that is able to respond effectively to various printing applications, Kao said.

This work complements Kao’s work in developing what it claimed was the world’s first water-based pigment inkjet ink for printing on film materials used in flexible packaging. The newly developed ink is based on Kao’s pigment nano dispersion technology and is free of volatile organic compounds (VOCs).

The acquisition, which will be executed through one of Kao’s European subsidiaries, is scheduled to complete in April 2017.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

The Start-up Platform for Chemistry & Life Sciences

The tasks range from employee protection, site security and crisis management to IT, OT and production security.

most read

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.